Indian patients no longer need to look abroad for advanced treatment,” said Dr. Sharat Damodar, Senior Consultant, Haematologist and Head of Adult BMT at Narayana Health City, Bengaluru and Chairman of the Oncology Collegium at Narayana Health.
Three-Year Cancer Remissions Mark Milestone for CAR T-Cell Therapy at Narayana Health City
Bengaluru, India 18th June, 2025– In a landmark development for cancer care in India, three patients treated with CAR T-cell therapy for relapsed follicular lymphoma at Narayana Health City, Bengaluru, have completed three years of successful follow-up—making this one of the longest documented survivals post-CAR T therapy in South India.
Chimeric Antigen Receptor T-cell (CAR T) therapy, a cutting-edge immunotherapy, has become a beacon of hope for patients with relapsed or treatment-resistant lymphoma. India now produces CAR T therapy domestically, with two CDSCO-approved products—NEXCAR19 and QARTEMI—making this life-saving treatment more accessible and affordable.
Ms. Perumala (name change...